Ownership and insider activity for Enanta Pharmaceuticals, Inc. (ENTA): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Enanta Pharmaceuticals, Inc. is a biotechnology firm dedicated to discovering and advancing small molecule therapies designed to combat a range of viral infections and various liver conditions. Its research and development efforts are primarily focused on addressing pathogens such as respiratory syncytial virus (RSV), SARS-CoV-2, human metapneumovirus (hMPV), and the hepatitis B virus (HBV).
Price
| Price | $12.70 |
| Market Cap | $369M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-08-08 | Rottinghaus Scott T. | F-InKind | 1,467 | $20K |
| 2026-03-11 | Vance Terry | A-Award | 20,000 | $283K |
| 2026-03-11 | Russell Lesley | A-Award | 20,000 | $283K |
| 2026-03-11 | Peterson Kristine | A-Award | 20,000 | $283K |
| 2026-03-11 | Hata Yujiro S | A-Award | 20,000 | $283K |
| 2026-03-11 | FOLETTA MARK G | A-Award | 20,000 | $283K |
| 2026-03-11 | CARTER BRUCE L A | A-Award | 20,000 | $283K |
| 2026-02-12 | Kowalsky Matthew Paul | A-Award | 4,175 | |
| 2026-02-12 | Kowalsky Matthew Paul | F-InKind | 1,902 | $27K |
| 2026-02-12 | Kowalsky Matthew Paul | A-Award | 1,318 |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $16.6M | $65.7M | $63.9M | $51.2M | $87.1M | $57.2M | $44.0M | $85.4M | $37.2M | $32.3M |
| Short-term Investments | $193.5M | $158.0M | $244.8M | $284.0M | $299.5M | $186.8M | $205.2M | $284.5M | $211.0M | $156.6M |
| Receivables | $12.8M | $10.6M | $67.2M | $51.3M | $23.5M | $60.8M | $49.0M | $39.6M | $38.6M | $6.9M |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $232.2M | $237.8M | $380.4M | $401.8M | $436.8M | $319.0M | $311.7M | $422.8M | $299.9M | $204.3M |
| Property, Plant & Equipment | $8.0M | $8.0M | $8.4M | $10.9M | $15.6M | $10.7M | $29.7M | $34.7M | $73.3M | $72.9M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $281.3M | $326.6M | $414.2M | $489.8M | $490.8M | $440.9M | $380.6M | $462.3M | $376.7M | $280.7M |
| Accounts Payable | $3.4M | $3.7M | $4.7M | $6.7M | $5.7M | $9.5M | $6.0M | $4.1M | $8.0M | $1.9M |
| Short-term Debt | 0 | 0 | 0 | 0 | $4.3M | 0 | 0 | 0 | $34.5M | $30.7M |
| Total Current Liabilities | $7.9M | $21.0M | $16.0M | $22.6M | $24.2M | $36.2M | $29.8M | $62.8M | $57.5M | $48.6M |
| Long-term Debt | 0 | 0 | 0 | 0 | $1.5M | $1.5M | $1.4M | 0 | $136.1M | $112.4M |
| Total Liabilities | $11.3M | $25.0M | $20.5M | $27.3M | $35.2M | $41.4M | $59.3M | $245.5M | $247.8M | $216.0M |
| Retained Earnings | $27.6M | $45.4M | $117.4M | $163.7M | $127.6M | $48.6M | -$73.2M | -$207.0M | -$323.0M | -$404.9M |
| Total Equity | $269.9M | $301.7M | $393.7M | $462.5M | $455.6M | $399.4M | $321.3M | $216.7M | $128.8M | $64.7M |
| Total Debt | $531000 | $458000 | $293000 | $200000 | $9.6M | $6.8M | $26.7M | $26.5M | $226.1M | $201.1M |
| Net Debt | -$209.6M | -$223.2M | -$308.4M | -$335.0M | -$377.1M | -$237.2M | -$222.5M | -$343.4M | -$22.1M | $12.2M |
| Working Capital | $224.3M | $216.8M | $364.4M | $379.2M | $412.7M | $282.8M | $281.9M | $360.0M | $242.3M | $155.8M |
Financial Health
| Debt / Equity | 0.55 |
| Current Ratio | 3.76 |
Profitability
| Return on Equity | -61.84% |
| Return on Invested Capital | -23.81% |
| Return on Assets | -21.30% |
| Gross Margin | 98.15% |
| Operating Margin | -89.99% |
| Net Margin | -96.89% |
Related companies: ASMB · AVIR · CRBU · FHTX · IMRX · NAUT · PRLD
Explore sector: Healthcare · Biotechnology
More sections of ENTA: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks